Activity and Safety of Brentuximab Vedotin (SGN-35) in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL)


Activity and Safety of Brentuximab Vedotin (SGN-35) in Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL)
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Steven M Horwitz, MD (12/29/10)

Shustov AR et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Proc ASH 2010;Abstract 961.

Dr Horwitz is Assistant Attending in the Division of Hematologic Oncology’s Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, New York.